In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based ... both have a long duration of action, allowing once-daily administration.

Metabolic control can be improved markedly by administration of exogenous GLP-1, but the ... that inhibit DPP-4, thereby prolonging the duration of endogenous incretin action, have, therefore ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study,” published in ...

Sarah M. Baxter, from Queen’s University Belfast in Northern Ireland, and colleagues investigated if GLP-1 RA use compared to use of dipeptidyl peptidase-4 inhibitors (DPP-4is) was associated ...

Of over 350,000 adults with type 2 diabetes, thyroid cancer risk was significantly higher within the first year after GLP-1 agonist initiation compared with SGLT2 inhibitors, DPP-4 inhibitors ...

DPP-4 is an enzyme (a natural chemical) that breaks down hormone GLP-1. GLP-1 helps the body lower blood sugar levels by causing the pancreas to produce insulin after a meal. So, more GLP-1 means more ...

"GLP-1 also tells the brain that there's fluid in the gastrointestinal tract, so you should start feeling full and stop ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i ... dipeptidyl peptidase-4 inhibitors (DPP-4i) in male patients with ...